|
 CytRx Corporation (NASDAQ: CYTR)
CYTR previously reported that favorable data from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate aldoxorubicin (formerly INNO-206) in patients with advanced soft tissue sarcoma was presented at the Sarcoma Poster-Discussion Session (Hall H) at the ESMO (European Society of Medical Oncology) 2012 Congress in Vienna, Austria. The presentation, entitled ?INNO-206 (aldoxorubicin) Is An Active Drug For Relapsed Soft Tissue Sarcoma,? was given by renowned sarcoma expert Sant P. Chawla, M.D., Director of the Sarcoma Oncology Center in Santa Monica, CA. 
The data from the aldoxorubicin Phase 1b/2 clinical trial showed clinical benefit (defined as partial response and stable disease of more than four months following up to eight cycles of treatment) with aldoxorubicin at the maximum tolerated dose in 10 of 13 (77%) evaluable patients with relapsed or refractory soft tissue sarcoma. CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, recently initiated both a Phase 2 trial for patients with advanced pancreatic ductal adenocarcinomas and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and plans to meet with the FDA in the fourth quarter of 2012 to discuss a potential Phase 3 pivotal trial as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer, and is in a Phase 2 clinical trial as a treatment for acute promyelocytic leukemia (APL). The Company completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about the Company, visit www.cytrx.com. ****  API Technologies Corp. (NASDAQ: ATNY)
ATNY reported that it has received a new $1.7 million order to provide high power/small signal amplifiers for use in electronic warfare systems. The order was placed by a prime U.S. Department of Defense contractor. Deliveries are expected over the next 12 months with an estimated lifetime revenue potential of $20 million. 
API Technologies designs, develops and manufactures electronic systems, subsystems, RF and secure solutions for technically demanding defense, aerospace and commercial applications. API Technologies' customers include many leading Fortune 500 companies. API Technologies trades on the NASDAQ under the symbol ATNY. For further information, please visit the Company website at www.apitech.com. ****  Crown Equity Holdings Inc. (CRWE)
CRWE has launched a online service companies CRWE Real Estate. CRWE launched CRWE Real Estate to provide a global portal for property listings at a fee of only $1 a day. CRWE Real Estate (www.crwerealestate.com)mission is to empower consumers with information and tools to make smart decisions about homes, real estate and mortgages. CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them. Crown Equity Holdings advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. For more information about Crown Equity Holdings Inc. visit www.crownequityholdings.com. **** To view recent article please visit http://crweselect.com/30872/stock-alerts/state-street-corporation-reports-3q-2012-gaap-results-stt-cytr/ *********** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. (Read Full Disclaimer at http://crweselect.com/disclaimer).
Related Articles -
API Technologies Corp., Crown Equity, CROWN EQUITY HLD, Crown Equity Holdings, CRWE, CRWE Real Estate, CRWE stock chart, crweselect, CYTR, CytRx, CytR,
| 
